D. Boral Capital reaffirmed their buy rating on shares of CervoMed (NASDAQ:CRVO – Free Report) in a research report released on Monday,Benzinga reports. The brokerage currently has a $10.00 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈